The Pharmacology and Therapeutic Potential of Serotonin Receptor Agonists and Antagonists
- 1 January 1988
- book chapter
- Published by Elsevier
Abstract
No abstract availableThis publication has 100 references indexed in Scilit:
- Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptorsLife Sciences, 1985
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agentsLife Sciences, 1984
- Effect of 8-hydroxy-2-(di-n-propylamino) tetralin on rat prolactin secretionJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1984
- Behavioral and biochemical evidence for serotonergic actions of tetrahydro-β-carbolinesLife Sciences, 1982
- 8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activityJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1982
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981
- Trazodone, a central serotonin antagonist and agonistJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1979
- Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by ratsLife Sciences, 1979
- The effects of quipazine on serotonin metabolism in rat brainLife Sciences, 1976
- Influence of quipazine, a potential anti-parkinsonian agent on the uptake of 3H-dopamine and 3H-serotonin into rat striatal tissue in vitroLife Sciences, 1973